It is not yet clear whether the genetic diagnosis of FH patients as double-heterozygotes is clinically relevant, because in most of the cases, the level of LDL-C is sufficiently treated with lipid-lowering drugs, including statins and PCSK9 inhibitors. Here, PCSK9 is linked to familial hyperaldosteronism.